Clinical Trials Browser

Expanded_access × Plasma cell × 1 year × Clear all

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT05346835 2026-02-13

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Available

Plasma cell

Multiple Myeloma

NCT03123029 2026-01-30

Expanded Access to Venetoclax

Available

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05161598 2025-12-16

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

No longer available

Plasma cell

Multiple Myeloma

NCT04771078 2025-12-12

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Available

Plasma cell

Multiple Myeloma

NCT05100134 2025-12-09

Managed Access Programs for LDK378, Ceritinib

Available

LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Approved for marketing

Plasma cell

Multiple Myeloma, Recurrence

NCT05164250 2025-11-10

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Approved for marketing

Plasma cell

Multiple Myeloma, Recurrence

NCT05463939 2025-06-15

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Approved for marketing

Plasma cell

Multiple Myeloma, Recurrence

NCT04452994 2025-06-13

Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma

No longer available

Plasma cell

Multiple Myeloma

Clinical Trials

KEAP

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Expanded Access to Venetoclax

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Managed Access Programs for LDK378, Ceritinib

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma